THURSDAY, May 8, 2025 (HealthDay News) — Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published online May 1 in The Lancet Child & Adolescent Health. Dewan Md. Sumsuzzman, Ph.D., from York University in Toronto, and colleagues conducted a systematic review and […]
The post Nirsevimab Effective for Reducing Burden of RSV in Infants first appeared on Physician’s Weekly.
